Silencers and Stabilizers in ATTR-CM: Challenging Assumptions

The therapeutic landscape for transthyretin amyloid cardiomyopathy (ATTR-CM) has evolved rapidly. With the advent of transthyretin (TTR) stabilizers such as tafamidis and acoramidis, and more recently, gene silencers like vutrisiran, we now have multiple disease-modifying options. But a European Journal of Heart Failure editorial article by Falk and colleagues challenges a key assumption: that deeper suppression of TTR necessarily translates into superior cardiac outcomes.

A Shared Ceiling of Benefit

Both stabilizers and silencers aim to reduce amyloid formation, with stabilizers preventing tetramer dissociation and silencers reducing hepatic TTR production. In pivotal trials like ATTR-ACT, ATTRibute-CM, and HELIOS-B, each class significantly reduced mortality and heart failure (HF) events compared with placebo.

However, a critical observation unites these studies: neither strategy meaningfully improved biomarkers such as NT-proBNP or functional capacity (6-minute walk distance) relative to baseline. Progression slowed, but reversal did not occur. Moreover, a substantial proportion of treated patients—particularly those entering with advanced NYHA class or elevated NT-proBNP—continued to deteriorate.

The expectation that silencers would outperform stabilizers in ATTR-CM, extrapolated from familial amyloid polyneuropathy (FAP), has not been realized in cardiac disease. Relative risk reductions appear broadly similar across mechanisms.

This raises a fundamental question: are we overestimating the role of ongoing amyloid production in late-stage cardiac progression?

Variant vs. Wild-Type

A key insight from the article is that wild-type and variant ATTR may not be interchangeable entities. In FAP, mutant TTR monomers exert direct neurotoxicity, which may explain the greater impact of profound TTR suppression in neuropathic disease. In contrast, ATTR-CM—particularly wild-type disease—appears primarily infiltrative rather than toxic.

The common Val122Ile variant, associated with a more aggressive cardiac phenotype, further underscores biological heterogeneity. Wild-type TTR instability is comparatively modest, and age-related oxidative modifications may contribute to amyloidogenesis.

For clinicians, this distinction matters. Extrapolating neuropathy data to cardiomyopathy may misguide expectations regarding treatment magnitude.

When Amyloid Is No Longer the Only Problem

Histopathologic studies reveal that advanced ATTR-CM is not solely an amyloid deposition disorder. Extensive extracellular fibrosis and collagen deposition accompany amyloid infiltration. These fibrotic changes are unlikely to regress with therapies that merely halt additional amyloid formation as patients with more advanced disease respond less robustly, silencers do not outperform stabilizers despite deeper TTR suppression, and biomarkers plateau rather than improve.

In practical terms, once myocardial fibrosis becomes substantial, disease progression may become partially independent of active amyloid production.

Implications for Clinical Practice

The therapeutic ceiling observed across drug classes suggests that earlier diagnosis may be more consequential than deeper TTR suppression. Initiating treatment before substantial fibrosis develops may preserve myocardial function more effectively than attempting to arrest progression in advanced stages. For heart failure specialists, this reinforces vigilance in older adults with unexplained left ventricular hypertrophy, discordant low-voltage ECG findings, or HFpEF phenotypes that defy conventional explanation.

Emerging imaging modalities may further refine this approach. Cardiac magnetic resonance–derived extracellular volume quantifies overall expansion but does not distinguish amyloid from fibrosis. PET tracers such as florbetapir and evuzamitide can more specifically assess amyloid burden, while 68Ga-labeled fibroblast activation protein inhibitor imaging is being explored as a marker of active fibrosis. If validated in ATTR-CM, such techniques could help identify patients whose progression reflects fibrotic remodeling rather than active deposition, potentially guiding therapeutic escalation toward amyloid-depleting antibodies now under investigation.

The broader message is not that silencers and stabilizers are equivalent in all respects, but that suppressing amyloid production may not fully address the downstream myocardial consequences of the disease. As gene-editing strategies enter clinical trials, expectations should remain tempered; their biological effect resembles that of current silencers. The next meaningful gains in outcomes may depend less on how completely TTR is silenced and more on whether existing deposits can be removed and fibrosis modulated.

In reframing the question from “Which mechanism is stronger?” to “What drives progression once amyloid is established?”, the field may uncover its next therapeutic breakthrough.

Reference:
Falk RH, Cuddy SAM, Itzhaki Ben Zadok O. Silencers versus stabilizers in amyloid cardiomyopathy. Are we asking the wrong questions? Eur J Heart Fail. 2025;27(4):623-627. doi:10.1002/ejhf.3614